Bente Glintborg

Bente Glintborg

Clinical Associate Professor

Member of:

  • Internal Medicine: Rheumatology


Publication year:
All
1 - 10 out of 14Page size: 10
  1. 2019
  2. Published

    Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial

    Grøn, K. L., Glintborg, Bente, Nørgaard, M., Mehnert, F., Østergaard, Mikkel, Dreyer, L., Krogh, N. S., Bjørner, Jakob Bue & Hetland, Merete Lund, 2019, In: Arthritis & Rheumatology. 71, 12, p. 1997-2004 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    DIRECT COMPARISON OF CERTOLIZUMAB PEGOL, ABATACEPT AND BIOSIMILAR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN ROUTINE CARE. OBSERVATIONAL DATA FROM THE DANISH DANBIO REGISTRY ANALYZED LIKE A RANDOMIZED CLINICAL TRIAL

    Grøn, K., Glintborg, Bente, Nørgaard, M., Mehnert, F., Stergaard, M., Dreyer, L., Krogh, N. S., Bjørner, Jakob Bue & Hetland, Merete Lund, 2019, In: Annals of the Rheumatic Diseases. 78, Suppl 2, p. 1391-1391 SAT0595.

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  4. Published

    Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?

    Glintborg, Bente, Ibsen, R., Bilbo, R. E. Q., Hetland, Merete Lund & Kjellberg, J., 2019, In: RMD Open. 5, 2, 9 p., e001016.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    OVERALL INFECTION RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ABATACEPT, RITUXIMAB AND TOCILIZUMAB: AN OBSERVATIONAL COHORT STUDY

    Grøn, K., Glintborg, Bente, Mehnert, F., Østergaard, Mikkel, Dreyer, L., Nørgaard, M., Krogh, N. S. & Hetland, Merete Lund, 2019, In: Annals of the Rheumatic Diseases. 78, Suppl 2, p. 630 THU0667.

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  6. Published

    Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Canet, L. M., Sánchez-Maldonado, J. M., Cáliz, R., Rodríguez-Ramos, A., Lupiañez, C. B., Canhão, H., Martínez-Bueno, M., Escudero, A., Segura-Catena, J., Sorensen, S. B., Hetland, M. L., Soto-Pino, M. J., Ferrer, M. A., García, A., Glintborg, B., Filipescu, I., Pérez-Pampin, E., González-Utrilla, A., Nevot, M. Á. L., Conesa-Zamora, P. & 10 others, Broeder, A. D., De Vita, S., Jacobsen, S. E. H., Collantes-Estevez, E., Quartuccio, L., Canzian, F., Fonseca, J. E., Coenen, M. J. H., Andersen, V. & Sainz, J., 2019, In: The Pharmacogenomics Journal. 19, 1, p. 83-96 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    RISK OF HOSPITALIZED INFECTION IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS TREATED WITH BIOLOGICAL DRUGS: A MATCHED COHORT STUDY

    Krabbe, S., Grøn, K. L., Glintborg, Bente, Mehnert, F., Jarbøl, D. E., Østergaard, Mikkel & Hetland, Merete Lund, 2019, In: Annals of the Rheumatic Diseases. 78, Suppl 2, p. 214 OP0266.

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  8. Published

    Risk factors for Staphylococcus aureus bacteremia in patients with rheumatoid arthritis and incidence compared with the general population: Protocol for a Danish nationwide observational cohort study

    Dieperink, S. S., Glintborg, Bente, Oestergaard, L. B., Nørgaard, M., Benfield, Thomas, Mehnert, F., Petersen, A. & Hetland, Merete Lund, 2019, In: BMJ Open. 9, 9, 7 p., e30999.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

    Grøn, K. L., Arkema, E. V., Glintborg, Bente, Mehnert, F., Østergaard, Mikkel, Dreyer, L., Nørgaard, M., Krogh, N. S., Askling, J. & Hetland, Merete Lund, 2019, In: Annals of the Rheumatic Diseases. 78, 3, p. 320-327

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

    Glintborg, B., Loft, A. G., Omerovic, E., Hendricks, O., Linauskas, A., Espesen, J., Danebod, K., Jensen, D. V., Nordin, H., Dalgaard, E. B., Chrysidis, S., Kristensen, S., Raun, J. L., Lindegaard, H., Manilo, N., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard Pedersen, D., Sørensen, I. J., Andersen, L. S. & 4 others, Grydehøj, J., Mehnert, F., Krogh, N. S. & Hetland, Merete Lund, 2019, In: Annals of the Rheumatic Diseases. 78, 2, p. 192-200

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

    Lindström, U., Glintborg, Bente, Di Giuseppe, D., Nordström, D., Aarrestad Provan, S., Gudbjornsson, B., Askling, J., Hetland, Merete Lund, Aaltonen, K., Krogh, N. S., Geirsson, A. J. & Jacobsson, L. T. H., 2019, In: RMD Open. 5, 2, 8 p., e001079.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 Next

ID: 212553036